PMID- 18520048
OWN - NLM
STAT- MEDLINE
DCOM- 20080630
LR  - 20190720
IS  - 0918-6158 (Print)
IS  - 0918-6158 (Linking)
VI  - 31
IP  - 6
DP  - 2008 Jun
TI  - Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint 
      swelling in established monkey collagen-induced arthritis.
PG  - 1159-63
AB  - We examined if tocilizumab, humanized anti-interleukin-6 receptor (IL-6R) 
      antibody, can ameliorate joint swelling after the onset of arthritis in 
      collagen-induced arthritis (CIA). CIA was induced by the immunization of bovine 
      type II collagen in female cynomolgus monkeys. Tocilizumab (30 mg/kg) was 
      administered weekly for 4 weeks after the onset of arthritis. Swelling of 16 
      proximal interphalangeal (PIP) joints of hands and feet was monitored by 
      measuring the longitudinal and transverse axes of PIP joints and the oval area of 
      each PIP was calculated. Serum was collected once a week after tocilizumab 
      injection and blood chemistry, IL-6, soluble IL-6R (sIL-6R), and anti-tocilizumab 
      antibody were measured. At the end of study, histopathological examination of 
      joints was performed. Tocilizumab clearly reduced joint swelling in all animals 
      without anti-tocilizumab antibody. Histopathological study showed significant 
      decrease in the infiltration of neutrophils into inflamed joints was observed in 
      tocilizumab-treated animals. In conclusion, tocilizumab improved established 
      arthritis in monkey and monkey CIA model is useful for the analysis of 
      anti-arthritic effect of tocilizumab.
FAU - Uchiyama, Yasushi
AU  - Uchiyama Y
AD  - Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, 
      Japan.
FAU - Yorozu, Keigo
AU  - Yorozu K
FAU - Hashizume, Misato
AU  - Hashizume M
FAU - Moriya, Yoichiro
AU  - Moriya Y
FAU - Mihara, Masahiko
AU  - Mihara M
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antibodies)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biomarkers)
RN  - 0 (Collagen Type II)
RN  - 0 (Interleukin-6)
RN  - 0 (Receptors, Interleukin-6)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - I031V2H011 (tocilizumab)
SB  - IM
MH  - Animals
MH  - *Anti-Inflammatory Agents, Non-Steroidal
MH  - Antibodies/blood
MH  - Antibodies, Monoclonal/immunology/*pharmacology
MH  - Antibodies, Monoclonal, Humanized
MH  - Arthritis, Experimental/chemically induced/*drug therapy/pathology
MH  - Biomarkers
MH  - C-Reactive Protein/biosynthesis
MH  - *Collagen Type II
MH  - Edema/pathology/prevention & control
MH  - Female
MH  - Foot/pathology
MH  - Hand/pathology
MH  - Interleukin-6/blood
MH  - Joints/pathology
MH  - Macaca fascicularis
MH  - Neutrophil Infiltration/drug effects
MH  - Receptors, Interleukin-6/*antagonists & inhibitors/*immunology
EDAT- 2008/06/04 09:00
MHDA- 2008/07/01 09:00
CRDT- 2008/06/04 09:00
PHST- 2008/06/04 09:00 [pubmed]
PHST- 2008/07/01 09:00 [medline]
PHST- 2008/06/04 09:00 [entrez]
AID - JST.JSTAGE/bpb/31.1159 [pii]
AID - 10.1248/bpb.31.1159 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2008 Jun;31(6):1159-63. doi: 10.1248/bpb.31.1159.